Chr. Hansen establishes Scientific Advisory Board to further strengthen its human health business and microbiome efforts. The board members are internationally recognized thought leaders.
“We are the leading developer and provider of probiotic cultures for the dietary supplements and infant formula industries and in line with our Nature’s no. 1™ strategy we aim to continue to shape the probiotics market and explore next generation opportunities for using bacteria to improve human health,” explains Christian Barker, Executive VP, Health & Nutrition Division.
“In order to secure continuous and top qualified input and guidance as we explore the exciting opportunities in relation to the human microbiome and “second generation probiotics”, we are now establishing a world-class Scientific Advisory Board composed of a set of internationally recognized thought leaders in the field,” Barker continues.
The Scientific Advisory Board consists of:
- Mr Eric Claassen (Chairman), Professor at Erasmus Medical Centre Rotterdam and at Vrije Universiteit Amsterdam, the Netherlands
- Mr Gary D Wu, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, USA
- Mr Willem M de Vos, Professor of Microbiology, Wageningen University, the Netherlands, and Helsinki University, Finland
- Mr Robert JM Brummer, Professor of Gastroenterology and Clinical Nutrition, Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden
- Ms Ruth Thieroff-Ekerdt, Founder and Member, Panda Consulting, Mendham, USA
The role of the Scientific Advisory Board is to provide state-of-the-art advice, support and challenge to Chr. Hansen’s management team with respect to developing new probiotic products, guiding the portfolio expansion into the microbiome, clinical trials, and accessing relevant networks and partners across the world.
Says Chairman of the Advisory Board Eric Claassen: “The scientific breakthroughs that are occurring with respect to the role of bacteria in human health hold great promise. As the global leader within probiotics, Chr. Hansen is very well positioned to capitalize on these opportunities, and I look forward to working with the other members of the Advisory Board to help guide Chr. Hansen in capturing these opportunities”
The Scientific Advisory Board will work closely together with the Scientific Committee of Chr. Hansen’s Board of Directors.
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.